1. RETRACTED ARTICLE: Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
- Author
-
Mohamed Elbahnasawy, Rehab Badawi, Shaimaa Soliman, Manal H El-Sayed, Hany Dabbous, Ahmed F Sherief, Fatma F S Ebeid, Mohamed Awad Tageldin, Sherief Abd-Elsalam, and Mohamed Samir Abd El Ghafar
- Subjects
Mechanical ventilation ,0303 health sciences ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,030306 microbiology ,medicine.medical_treatment ,General Medicine ,Biology ,Favipiravir ,Virology ,law.invention ,Clinical trial ,03 medical and health sciences ,Randomized controlled trial ,law ,Chloroquine ,Internal medicine ,medicine ,Hospital stay ,030304 developmental biology ,medicine.drug - Abstract
No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation.ClinicalTrials.gov Identifier NCT04351295. more...
- Published
- 2021
- Full Text
- View/download PDF